Costs of autologous stem-cell transplantation in solid tumours [1]

Annals of Oncology

Volumn 12, Issue 1, 2001, Pages 131-

  Leoncini, O ^a   Prada, G A D ^b   Pedrazzoli, P ^c  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b IRCCS   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MYELOABLATIVE AGENT;

AUTOTRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; HEALTH CARE COST; HEALTH ECONOMICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMAN; INTENSIVE CARE; ITALY; LETTER; NATIONAL HEALTH SERVICE; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SOLID TUMOR; SPAIN; TREATMENT PLANNING;

EID: 0035132415     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008316926760     Document Type: Letter

References (5)

1. Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells in women with high risk stage II or III breast cancer: Five-year follow-up
2. Multicyclic dose-intensive chemotherapy with circulating progenitor cell support for high-risk primary breast cancer
3. Efficacy, toxicity and applic-ability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Ten years results
4. Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation
5. High-dose chemotherapy and autotransplants: A time for guidelines